| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Mario Luca Morieri, Mauro Rigato, Vera Frison, Natalino Simioni, Michele D'Ambrosio, Federica Tadiotto, Agostino Paccagnella, Annunziata Lapolla, Angelo Avogaro, Gian Paolo Fadin. Fixed versus flexible combination of GLP-1 receptor agonists with basal insulin in type 2 diabetes: A retrospective multicentre comparative effectiveness study. Diabetes, obesity & metabolism. vol 21. issue 11. 2020-09-28. PMID:31364233. |
fixed versus flexible combination of glp-1 receptor agonists with basal insulin in type 2 diabetes: a retrospective multicentre comparative effectiveness study. |
2020-09-28 |
2023-08-13 |
Not clear |
| Mario Luca Morieri, Mauro Rigato, Vera Frison, Natalino Simioni, Michele D'Ambrosio, Federica Tadiotto, Agostino Paccagnella, Annunziata Lapolla, Angelo Avogaro, Gian Paolo Fadin. Fixed versus flexible combination of GLP-1 receptor agonists with basal insulin in type 2 diabetes: A retrospective multicentre comparative effectiveness study. Diabetes, obesity & metabolism. vol 21. issue 11. 2020-09-28. PMID:31364233. |
the combination of basal insulin (bi) and glp-1 receptor agonists (glp-1ras) is a rational and effective therapy for patients with uncontrolled type 2 diabetes (t2d). |
2020-09-28 |
2023-08-13 |
Not clear |
| Zhao-Jun Wang, Yu-Fei Han, Fang Zhao, Guang-Zhao Yang, Li Yuan, Hong-Yan Cai, Jun-Ting Yang, Christian Holscher, Jin-Shun Qi, Mei-Na W. A dual GLP-1 and Gcg receptor agonist rescues spatial memory and synaptic plasticity in APP/PS1 transgenic mice. Hormones and behavior. vol 118. 2020-09-28. PMID:31765661. |
oxm activates glucagon-like peptide 1 (glp-1) and glucagon (gcg) receptors, facilitates insulin signaling and has neuroprotective effects against aβ |
2020-09-28 |
2023-08-13 |
mouse |
| Le Gao, Shuqing Yu, Andrea Cipriani, Shanshan Wu, Yi Huang, Zilu Zhang, Jun Yang, Yixin Sun, Zhirong Yang, Sanbao Chai, Yuan Zhang, Linong Ji, Siyan Zhan, Feng Su. Neurological Manifestation of Incretin-Based Therapies in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. Aging and disease. vol 10. issue 6. 2020-09-28. PMID:31788342. |
compared to insulin, thiazolidinediones, or placebo, glp-1 ras statistically significantly increased the risk of dizziness (odds ratios [ors]: 1.92, 1.57, and 1.40, respectively) and headache (ors: 1.34, 1.41, and 1.18, respectively). |
2020-09-28 |
2023-08-13 |
Not clear |
| Cheli Melzer-Cohen, Gabriel Chodick, Shiran Naftelberg, Naim Shehadeh, Avraham Karasi. Metabolic Control and Adherence to Therapy in Type 2 Diabetes Mellitus Patients Using IDegLira in a Real-World Setting. Diabetes therapy : research, treatment and education of diabetes and related disorders. vol 11. issue 1. 2020-09-28. PMID:31808132. |
insulin degludec/liraglutide (ideglira) is a fixed-ratio combination (frc) of basal insulin and glucagon-like protein-1 receptor agonist (glp-1 ra) that has demonstrated glycemic and metabolic benefits in patients with type 2 diabetes mellitus (t2dm) in both randomized controlled trials and real-world studies. |
2020-09-28 |
2023-08-13 |
Not clear |
| Kyung-Ah Park, Zhen Jin, Jong Youl Lee, Hyeong Seok An, Eun Bee Choi, Kyung Eun Kim, Hyun Joo Shin, Eun Ae Jeong, Kyoung Ah Min, Meong Cheol Shin, Gu Seob Ro. Long-Lasting Exendin-4 Fusion Protein Improves Memory Deficits in High-Fat Diet/Streptozotocin-Induced Diabetic Mice. Pharmaceutics. vol 12. issue 2. 2020-09-28. PMID:32079069. |
glucagon-like peptide 1 (glp-1) mimetics have been approved as an adjunct therapy for glycemic control in type 2 diabetic patients for the increased insulin secretion under hyperglycemic conditions. |
2020-09-28 |
2023-08-13 |
mouse |
| Lotte Bjerre Knudse. Inventing Liraglutide, a Glucagon-Like Peptide-1 Analogue, for the Treatment of Diabetes and Obesity. ACS pharmacology & translational science. vol 2. issue 6. 2020-09-28. PMID:32259078. |
glucagon-like peptide-1 (glp-1) has been in focus since the early 1980s as a long looked for incretin hormone, released from the gastrointestinal tract and with an important effect on glucose-dependent insulin secretion, providing efficient glucose lowering, with little risk for hypoglycemia. |
2020-09-28 |
2023-08-13 |
Not clear |
| Enrico Torre, Giacomo M Bruno, Sergio Di Matteo, Chiara Martinotti, Maria Chiara Valentino, Luigi C Bottaro, Giorgio L Colomb. Economic Evaluation of Dulaglutide vs Traditional Therapies: Implications of the Outcomes of the Rewind Study. ClinicoEconomics and outcomes research : CEOR. vol 12. 2020-09-28. PMID:32308446. |
the aim of our study is to evaluate the economic impact of dulaglutide, a weekly glp-1 receptor agonist, on the treatment of diabetic patients as an alternative to both high dose sulphonylureas and insulin basalization at the failure of oral therapies alone. |
2020-09-28 |
2023-08-13 |
Not clear |
| Hitomi Sano, Eriko Kudo, Takeshi Yamazaki, Tomoshiro Ito, Kinya Hatakeyama, Nobuaki Kawamur. Efficacy of sodium-glucose cotransporter 2 inhibitor with glucagon-like peptide-1 receptor agonist for the glycemic control of a patient with Prader-Willi syndrome: a case report. Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology. vol 29. issue 2. 2020-09-28. PMID:32313377. |
in addition to glp-1 receptor agonists, sglt2 inhibitors may be a potential approach for the management of dm in pws, especially in young patients whose pancreatic insulin secretion capabilities are still preserved. |
2020-09-28 |
2023-08-13 |
Not clear |
| Alexander L Ticho, Pooja Malhotra, Pradeep K Dudeja, Ravinder K Gill, Waddah A Alrefa. Bile Acid Receptors and Gastrointestinal Functions. Liver research. vol 3. issue 1. 2020-09-28. PMID:32368358. |
interestingly, tgr5 induces the secretion of glucagon-like peptide-1 (glp-1) from l-cells to enhance insulin secretion and modulate glucose metabolism. |
2020-09-28 |
2023-08-13 |
Not clear |
| Li Ma, Xinyu Cao, Xiaotong Ye, Jianping Ye, Yongning Su. Sennoside A Induces GLP-1 Secretion Through Activation of the ERK1/2 Pathway in L-Cells. Diabetes, metabolic syndrome and obesity : targets and therapy. vol 13. 2020-09-28. PMID:32425572. |
glucagon-like peptide-1 (glp-1) is secreted from the intestinal l-cells to stimulate insulin secretion in the blood glucose control. |
2020-09-28 |
2023-08-13 |
mouse |
| Markolf Hanefeld, Holger Fleischmann, Thorsten Siegmund, Jochen Seufer. Rationale for Timely Insulin Therapy in Type 2 Diabetes Within the Framework of Individualised Treatment: 2020 Update. Diabetes therapy : research, treatment and education of diabetes and related disorders. vol 11. issue 8. 2020-09-28. PMID:32564335. |
recently published guidelines therefore recommend patient-centred risk/benefit-balanced use of oral glucose-lowering drugs or a glucagon-like peptide 1 (glp-1) receptor agonist, or switching to insulin with glycated haemoglobin (hba |
2020-09-28 |
2023-08-13 |
Not clear |
| Tuan Dinh Le, Nga Thi Phi Nguyen, Son Tien Nguyen, Hoa Thi Thanh Tran, Lan Thi Ho Nguyen, Hoang Huy Duong, Ha Manh Nguyen, Binh Nhu D. Sitagliptin Increases Beta-Cell Function and Decreases Insulin Resistance in Newly Diagnosed Vietnamese Patients with Type 2 Diabetes Mellitus. Diabetes, metabolic syndrome and obesity : targets and therapy. vol 13. 2020-09-28. PMID:32606870. |
to investigate effects of sitagliptin on the enhancement of beta-cell function, reducing insulin resistance, serum glucagon like peptide-1 (glp-1) concentrations and blood glucose in patients with type 2 diabetes mellitus (t2d) and suggest one of the underlying mechanisms on beta-cell function and insulin resistance. |
2020-09-28 |
2023-08-13 |
Not clear |
| Russell D Dolan, Ahmad Najdat Bazarbashi, Amy Lo, Benjamin N Smit. Liraglutide-Induced Hemorrhagic Pancreatitis in a Nondiabetic Patient. ACG case reports journal. vol 7. issue 5. 2020-09-28. PMID:32607380. |
liraglutide is a glucagon-like peptide 1 (glp-1) analog with a primary effect of increased glucose-dependent insulin secretion and decreased gastric emptying. |
2020-09-28 |
2023-08-13 |
Not clear |
| Young-Kook Kim, Oh Yoen Kim, Juhyun Son. Alleviation of Depression by Glucagon-Like Peptide 1 Through the Regulation of Neuroinflammation, Neurotransmitters, Neurogenesis, and Synaptic Function. Frontiers in pharmacology. vol 11. 2020-09-28. PMID:32922295. |
glucagon-like peptide-1 (glp-1), which is secreted from gut cells and hindbrain areas, has been studied in metabolic diseases such as obesity and diabetes, and was shown to control glucose metabolism and insulin resistance. |
2020-09-28 |
2023-08-13 |
Not clear |
| Hong Liu, Yan-Li Zhan, Guo-Jing Luo, Ling-Ling Zou, Yun Li, Hong-Yun L. Liraglutide and Insulin Have Contrary Effects on Adipogenesis of Human Adipose-Derived Stem Cells via Wnt Pathway. Diabetes, metabolic syndrome and obesity : targets and therapy. vol 13. 2020-09-28. PMID:32943896. |
glucagon-like peptide-1 (glp-1) has been reported to have beneficial impacts on improving human's metabolism and ameliorating insulin resistance. |
2020-09-28 |
2023-08-13 |
human |
| Caroline A Mulvaney, Gonçalo S Duarte, Joel Handley, David Jw Evans, Suresh Menon, Richard Wyse, Hedley Ca Emsle. GLP-1 receptor agonists for Parkinson's disease. The Cochrane database of systematic reviews. vol 7. 2020-09-25. PMID:32700772. |
glucagon-like peptide-1 (glp-1) receptor agonists, licensed for treatment of type 2 diabetes, work by stimulating glp-1 receptors in the pancreas, which triggers the release of insulin. |
2020-09-25 |
2023-08-13 |
Not clear |
| Rita Citraro, Michelangelo Iannone, Antonio Leo, Carmen De Caro, Valentina Nesci, Martina Tallarico, Karim Abdalla, Ernesto Palma, Franco Arturi, Giovambattista De Sarro, Andrew Constanti, Emilio Russ. Evaluation of the effects of liraglutide on the development of epilepsy and behavioural alterations in two animal models of epileptogenesis. Brain research bulletin. vol 153. 2020-09-24. PMID:31470253. |
liraglutide (lir) is a novel long-lasting glucagon-like peptide-1 (glp-1) analogue that facilitates insulin signalling and shows also neuroprotective properties in different brain disease models. |
2020-09-24 |
2023-08-13 |
mouse |
| Akiko Mizokami, Satoru Mukai, Jing Gao, Tomoyo Kawakubo-Yasukochi, Takahito Otani, Hiroshi Takeuchi, Eijiro Jimi, Masato Hirat. GLP-1 signaling is required for improvement of glucose tolerance by osteocalcin. The Journal of endocrinology. vol 244. issue 2. 2020-09-18. PMID:31693486. |
we previously showed that the effect of gluoc on insulin secretion is mediated predominantly by glucagon-like peptide-1 (glp-1) released from intestinal endocrine cells in response to gluoc stimulation. |
2020-09-18 |
2023-08-13 |
mouse |
| Preedajit Wongkrasant, Pawin Pongkorpsakol, Sasirin Chitwattananont, Wilasinee Satianrapapong, Nuttha Tuangkijkul, Chatchai Muanprasa. Fructo-oligosaccharides alleviate inflammation-associated apoptosis of GLP-1 secreting L cells via inhibition of iNOS and cleaved caspase-3 expression. Journal of pharmacological sciences. vol 143. issue 2. 2020-09-15. PMID:32229084. |
glucagon-like peptide 1 (glp-1) released from enteroendocrine (l) cells regulates insulin secretion. |
2020-09-15 |
2023-08-13 |
Not clear |